Stem Cell Lung-on-Chip for Heterogeneous Disease Modeling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current preclinical models of the human lung fail to capture the heterogeneous disease phenotypes and drug responses observed in patients, limiting the development of effective treatments for respiratory diseases.
Innovation Solution
An in vitro microfluidic 'organ-on-chip' device, specifically a stem cell-based Lung-on-Chip, that mimics the structure and function of lung tissue, allowing for the differentiation of cells into lung cells and the identification of cellular factors driving disease states, and supports drug testing and personalized medicine by using primary alveolar cells that express and secrete surfactants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional preclinical models are used, then model simplicity is maintained, but the ability to capture heterogeneous disease phenotypes and drug responses deteriorates
Solution Approach 1:
The patent segments the lung tissue into distinct microenvironments within the microfluidic device, including airway epithelium, alveolar epithelium, and vascular compartments. Each compartment can be independently cultured and manipulated, allowing for the study of specific disease phenotypes while maintaining overall system functionality. This segmentation enables heterogeneous disease modeling without requiring an entirely complex system redesign.
Solution Approach 2:
The patent implements a nested structure where multiple cell types and tissue layers are organized hierarchically within the microfluidic device. Epithelial cells form outer layers, while endothelial cells and stromal components are positioned internally, creating a nested architecture that mimics native lung tissue organization. This nesting allows complex tissue interactions to occur within a compact device structure.
2Reliability
If stem cells from the same patient are used, then immune response issues are reduced, but device complexity and differentiation protocol requirements increase
Solution Approach 1:
The patent employs preliminary differentiation protocols that convert patient-derived stem cells into lung-specific cell types before device integration. By pre-differentiating cells into airway or alveolar epithelial cells with defined characteristics, the system reduces immune rejection risks while establishing a standardized workflow that mitigates protocol complexity through repetition and optimization.
Solution Approach 2:
The patent utilizes parameter changes in the differentiation medium, including specific growth factors, cytokines, and biochemical cues, to guide stem cell fate determination. By systematically adjusting medium composition and physical parameters such as oxygen tension and mechanical stress, the protocol achieves reliable differentiation while providing a framework that can be standardized across different patient samples.
3Duration of action of moving object
If long-term cultures of functional Type II and Type I cells are maintained, then personalized medicine applications are enhanced, but culture duration and system stability requirements increase
Solution Approach 1:
The patent implements continuous culture conditions with sustained nutrient supply, waste removal, and environmental control within the microfluidic device. Culture media are continuously perfused through the device, maintaining optimal growth conditions for extended periods. This continuity enables long-term maintenance of functional Type II and Type I cells while providing a stable system through consistent parameter control.
Solution Approach 2:
The patent incorporates self-organizing properties of lung epithelial cells, where Type II cells automatically differentiate into Type I cells and form functional tissue structures without continuous external intervention. The system leverages intrinsic cellular programs and cell-cell interactions to maintain tissue homeostasis, reducing the burden of external control while extending culture duration and enhancing system reliability.
Data Source
AI summary
An in vitro microfluidic “organ-on-chip” device is described herein that mimics the structure and at least one function of specific areas of the epithelial system in vivo. In particular, a stem cell-based Lung-on-Chip is described. This in vitro microfluidic system can be used for modeling differentiation of cells on-chip into lung cells, e.g., a lung (Lung-On-Chip), bronchial (Airway-On-Chip; small-Airway-On-Chip), alveolar sac (Alveolar-On-Chip), etc., for use in modeling disease states of derived tissue, i.e. as healthy, pre-disease and diseased tissues. Additionally, stem cells under differentiation protocols for deriving (producing) differentiated lung cells off-chips may be seeded onto microfluidic devices at any desired point during the in vitro differentiation pathway for further differentiation on-chip or placed on-chip before, during or after terminal differentiation.